290 results
Page 3 of 15
6-K
3ah fde3lyhuwis
1 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
62xrwe4
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
togaq0fn0iqpnjtwz4
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
ttf eib10vzufjm
30 May 23
Current report (foreign)
6:11am
6-K
wy2at1qm 25p1vz
17 May 23
Current report (foreign)
6:02am
6-K
1wycd
11 May 23
Current report (foreign)
6:10am
6-K
pc5bd
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
7hs9bju
11 May 23
Current report (foreign)
6:07am
6-K
4o3zk9lo5
30 Mar 23
Current report (foreign)
6:19am
6-K
zzn9cjhwsxzj 0y1cn
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
2u5bs60
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
7m4jserm
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
wgv1qhh4bkwy05 yk
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
6sx59qna
30 Nov 22
Current report (foreign)
6:28am
6-K
ucacp4 9tg3cc6
4 Nov 22
Current report (foreign)
6:01am
6-K
EX-99.1
kehpdgdy reor
27 Oct 22
Current report (foreign)
6:01am
6-K
qtzbd2kf
14 Oct 22
Current report (foreign)
7:36am
6-K
tiphw0nxc40
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
il1xhmpi1mnpm2
23 Aug 22
Current report (foreign)
6:13am
6-K
EX-99.1
lek4eah
4 Aug 22
Current report (foreign)
6:07am